I'm not saying that this is happening, but what would happen if it were announced that at one of the major upcoming conferences UCLA would be presenting results from their trials with DCVax-L and Keytruda and/or Poly-ICLC.
We all know that many trials are currently ongoing in GBM. It's not that DCVax-L with Keytruda and/or Poly-ICLC cures everyone, it doesn't, however I believe the developers of other products in trials that show benefits on the current SOC will be eager to add their experimental products to new trials using DCVax-L, Keytruda and/or Poly-ICLC, plus their experimental product to see if they can achieve significantly greater survival than 50% or so at 5 years.
Dr. Liau, for one, certainly won't stop at 50% survival. I think she considers it her life's work and anything under 100% still represents an opportunity to improve. I believe that DCVax-L will play a role for the foreseeable future in her efforts, but all is not done when DCVax-L is approved and everyone's using it with Keytruda and/or Poly-ICLC.
Gary
Bullish
Market Data 
Markets 
AI
